GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » Total Equity

ATAI Life Sciences NV (FRA:9VC) Total Equity : €205.40 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Total Equity?

ATAI Life Sciences NV's total equity for the quarter that ended in Mar. 2024 was €205.40 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


ATAI Life Sciences NV Total Equity Historical Data

The historical data trend for ATAI Life Sciences NV's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV Total Equity Chart

ATAI Life Sciences NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
53.67 78.39 341.57 250.88 224.04

ATAI Life Sciences NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 224.76 199.03 251.60 224.04 205.40

ATAI Life Sciences NV Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

ATAI Life Sciences NV's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=269.119-45.082
=224.04

ATAI Life Sciences NV's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=247.591-42.195
=205.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ATAI Life Sciences NV Total Equity Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


ATAI Life Sciences NV (FRA:9VC) Business Description

Traded in Other Exchanges
Address
Wallstraße 16, Berlin, BB, DEU, 10179
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

ATAI Life Sciences NV (FRA:9VC) Headlines

No Headlines